Arjun Goyal - May 27, 2021 Form 3 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Director
Signature
/s/ Marella Thorell, attorney-in-fact
Stock symbol
CNTA
Transactions as of
May 27, 2021
Transactions value $
$0
Form type
3
Date filed
5/27/2021, 08:32 PM
Next filing
Jun 4, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CNTA Series A Preferred Shares May 27, 2021 Ordinary Shares 3.1M See footnote F1, F2, F3
holding CNTA Series A Preferred Shares May 27, 2021 Ordinary Shares 85.9K See footnote F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately prior to the closing of the initial public offering closing, Series A Preferred Shares will automatically convert on a one-to-one basis into Ordinary Shares without payment or further consideration. The resulting number of Ordinary Shares of the Issuer are shown in Column 3. The Series A Preferred Shares have no expiration date.
F2 Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F3 Held by Vida Ventures II, LLC ("Vida II Main Fund"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II Main Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4 Held by Vida Ventures II-A, LLC ("Vida II Parallel Fund"). VV Manager II is the manager of Vida II Parallel Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Remarks:

Exhibit 24 - Power of Attorney